ME Therapeutics extends option agreement with NRC for cancer drug asset

Vancouver biotechnology firm ME Therapeutics Holdings Inc. extended an option agreement with the National Research Council of Canada on October 10, 2026, according to a company press release. The agreement focuses on a proprietary nanobody-based CD22 binder developed by the government research organization.

The extended option agreement allows ME Therapeutics Holdings Inc. to maintain rights while evaluating the asset for drug development. Specifically, the company is focusing its target applications on the creation of novel immuno-oncology cancer drugs using the CD22 binder asset.

According to the press release, the extension gives ME Therapeutics Holdings Inc. additional time to perform pre-clinical work on the CD22 binder. The extension also allows the firm to complete its detailed licensing evaluation of the proprietary asset from the National Research Council of Canada.

Pre-Clinical Work and Drug Development

ME Therapeutics Holdings Inc. is a biotechnology company focused on the development of novel cancer-fighting treatments. By extending the option agreement with the National Research Council of Canada, the Vancouver-based firm continues its technical and operational assessment of the nanobody-based CD22 binder asset.

The primary target applications for the CD22 binder asset are within the field of immuno-oncology. ME Therapeutics Holdings Inc. plans to use the results from its pre-clinical work to guide future drug development decisions regarding the novel cancer-fighting treatments in its pipeline.

The agreement extension ensures that the company can perform ongoing pre-clinical work and evaluate potential licensing terms without interruption. The National Research Council of Canada developed the proprietary nanobody-based asset as part of its ongoing research in biological sciences and healthcare technology.

Corporate Listings and Market Information

ME Therapeutics Holdings Inc. maintains its corporate headquarters in Vancouver, British Columbia. The biotechnology firm operates in Canada and international equity markets through listings on two separate financial exchanges.

The company trades publicly on the Canadian Securities Exchange under the ticker symbol METX. Additionally, ME Therapeutics Holdings Inc. trades on the Frankfurt Stock Exchange under the ticker symbol Q9T.

The news of the agreement extension was formally announced in a press release dated October 10, 2026. The next step for ME Therapeutics Holdings Inc. involves completing its pre-clinical work and finishing its evaluation of the licensing agreement with the National Research Council of Canada.